Alnylam begins a PhII trial for amyloidosis RNAi treatment

Alnylam Pharmaceuticals ($ALNY) began a Phase II study of its RNAi drug designed to treat TTR-mediated amyloidosis, an inherited, fatal disease caused by genetic mutations. The company uses a GalNAc-siRNA platform to deliver the RNAi genetic silencers that target the mutated transthyretin (TTR) gene. The drug would be the first genetic treatment for the disease, which affects about 50,000 people worldwide. The subcutaneously delivered ALN-TTRsc is the most advanced GalNAc-conjugate RNAi drug in Alnylam's pipeline and the first to enter Phase II trials. Release

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…